Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biologics Approvals Face Orphan Issues In Early 1999; Nine Cleared In 1998

Executive Summary

Two FDA decisions about biologics applications in line for early approval in 1999, ReFacto and Rebif, could hinge on orphan exclusivity deliberations.

You may also be interested in...

Amgen Infergen Cleared For Hepatitis C Retreatment Following Relapse

Amgen's Infergen has expanded its labeling for use in the subsequent treatment of hepatitis C patients who relapse following initial treatment with interferon alfa-2b or Infergen.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts